NRx Pharma Announces Receipt of Positive Nasdaq Listing Determination
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals, Inc. (NRXP) received a positive determination from the Nasdaq Hearings Panel for its listing transfer to The Nasdaq Capital Market. The company must demonstrate compliance with a $35 million market value of listed securities and a $1.00 minimum bid price by April 16, 2024. NRx believes it has met the market value requirement and is working to meet the bid price requirement.
January 17, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals, Inc. is on track to transfer its listing to The Nasdaq Capital Market after meeting the market value requirement and working towards the $1.00 bid price requirement.
The positive listing determination by Nasdaq is a significant regulatory milestone for NRx Pharmaceuticals, indicating progress in the company's efforts to maintain its listing and potentially improving investor confidence. Meeting the Nasdaq Capital Market's requirements could lead to increased investor interest and support for the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100